Fortress Biotech Inc

NASDAQ:FBIOUnited States

Nov 14, 2024

Show headlines and story abstract

• -- Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q3 Revenue $14.6M, from 4:11PM ET on Thursday Nov 14, 2024 by MT Newswires

  4:11PM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: FBIO
  04:11 PM EST, 11/14/2024 (MT Newswires) -- ...

• Press Release: Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights, from 4:10PM ET on Thursday Nov 14, 2024 by Dow Jones

  4:10PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: FBIO
  Asset impairment -- -- 2,649 3,143 ---------- --------- ---------- --------- Total operating expenses 36,724 48,510 129,099 187,295 ---------- --------- ---------- --------- Loss from operations (22,095) (13,758) (86,544) (122,728) Other income (expense) Interest income 589 547 2,157 2,296 Interest expense and financing fee (6,209) (2,534) (10,933) (13,255) Gain (loss) on common stock warrant liabilities 19 4,542 (578) 10,708 Other income (expense) 1,071 620 1,334 (2,049) ---------- --------- ---------- --------- Total other income (expense) (4,530) 3,175 (8,020) (2,300) ---------- --------- ---------- --------- Loss before income tax expense (26,625) (10,583) (94,564) (125,028) Income tax expense (refund) 69 141 (24) 142 ---------- --------- ---------- --------- Net loss (26,694) (10,724) (94,540) (125,170) ========== ========= ========== ========= Net loss attributable to non-controlling interests 13,827 5,679 55,308 73,812 ---------- --------- ---------- --------- Net loss attributable to Fortress $ (12,867) $ (5,045) $ (39,232) $ (51,358) ========== ========= ========== ========= Preferred A dividends declared and paid and/or cumulated, and Fortress' share of subsidiary deemed dividends (2,173) (2,008) (7,006) (6,024) ---------- --------- ---------- --------- Net loss attributable to common stockholders $ (15,040) $ (7,053) $ (46,238) $ (57,382) ========== ========= ========== ========= Net loss per common share attributable to common stockholders - basic and diluted $ (0.76) $ (0.94) $ (2.43) $ (7.94) Weighted average common shares outstanding - basic and diluted 19,697,290 7,498,653 19,041,590 7,231,004
  

• Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights, from 4:10PM ET on Thursday Nov 14, 2024 by Dow Jones

  4:10PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: FBIO
  Asset impairment -- -- 2,649 3,143 ---------- --------- ---------- --------- Total operating expenses 36,724 48,510 129,099 187,295 ---------- --------- ---------- --------- Loss from operations (22,095) (13,758) (86,544) (122,728) Other income (expense) Interest income 589 547 2,157 2,296 Interest expense and financing fee (6,209) (2,534) (10,933) (13,255) Gain (loss) on common stock warrant liabilities 19 4,542 (578) 10,708 Other income (expense) 1,071 620 1,334 (2,049) ---------- --------- ---------- --------- Total other income (expense) (4,530) 3,175 (8,020) (2,300) ---------- --------- ---------- --------- Loss before income tax expense (26,625) (10,583) (94,564) (125,028) Income tax expense (refund) 69 141 (24) 142 ---------- --------- ---------- --------- Net loss (26,694) (10,724) (94,540) (125,170) ========== ========= ========== ========= Net loss attributable to non-controlling interests 13,827 5,679 55,308 73,812 ---------- --------- ---------- --------- Net loss attributable to Fortress $ (12,867) $ (5,045) $ (39,232) $ (51,358) ========== ========= ========== ========= Preferred A dividends declared and paid and/or cumulated, and Fortress' share of subsidiary deemed dividends (2,173) (2,008) (7,006) (6,024) ---------- --------- ---------- --------- Net loss attributable to common stockholders $ (15,040) $ (7,053) $ (46,238) $ (57,382) ========== ========= ========== ========= Net loss per common share attributable to common stockholders - basic and diluted $ (0.76) $ (0.94) $ (2.43) $ (7.94) Weighted average common shares outstanding - basic and diluted 19,697,290 7,498,653 19,041,590 7,231,004
  

• Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones

  4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: FBIO, ATXI
  
  discussed in our filings which we make with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.